Sunesis Overview
- Founded
- 1998

- Status
- Acquired/Merged
- Employees
- 8

- Latest Deal Type
- M&A
Sunesis General Information
Description
Sunesis Pharmaceuticals Inc is a US-based biopharmaceutical company. It focuses on the development and commercialization of its pipeline of oncology therapeutics for the treatment of solid and hematologic cancers. The product portfolio of the company includes Vosaroxin which is an anticancer quinolone derivative for the treatment of acute myeloid leukemia (AML). The company's other kinase inhibitor pipeline includes TAK-580, SNS-062, and SNS-229. Further, the firm's activities include conducting research and development internally and through corporate collaborators, in-licensing and out-licensing pharmaceutical compounds and technology, conducting clinical trials and raising capital. The firm derives substantially the majority of revenue from license and collaboration agreements.
Contact Information
- 395 Oyster Point Boulevard
- Suite 400
- South San Francisco, CA 94080
- United States
Sunesis Valuation & Funding
Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
---|---|---|---|---|---|---|
17. Merger/Acquisition | 24-Feb-2021 | 00000 | Completed | Generating Revenue | ||
16. Secondary Transaction - Open Market | 00000 | Completed | Generating Revenue | |||
15. PIPE | 25-Oct-2017 | 00000 | Completed | Generating Revenue | ||
14. Debt - General | 01-Apr-2016 | 0000 | 00000 | Completed | Clinical Trials - Phase 1 | |
13. PIPE | 01-Jan-2016 | 00000 | Completed | Generating Revenue | ||
12. Secondary Transaction - Open Market | 01-Jan-2014 | 00000 | Completed | Clinical Trials - Phase 1 | ||
11. Secondary Transaction - Open Market | 00000 | Completed | Clinical Trials - Phase 1 | |||
10. Secondary Transaction - Open Market | 31-Dec-2013 | 00000 | Completed | Clinical Trials - Phase 1 | ||
9. Debt - General | 19-Oct-2011 | $12M | $212M | Completed | Clinical Trials - Phase 1 | |
8. Secondary Transaction - Open Market | 01-Jan-2010 | $200M | Completed | Clinical Trials - Phase 1 |
Sunesis Comparisons
Industry
00000
00000000
PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.
Request a free trialSunesis Competitors (107)
Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
---|---|---|---|---|---|---|
Merus | Formerly VC-backed | Utrecht, Netherlands | 000 | 00000 | 000000000 | 00000 |
00000000 000000000 | Corporation | Watertown, MA | 000 | 00000 | 000000000 | 00000 |
0000000 | Formerly PE-Backed | Beijing, China | 0000 | 00.000 | 00000000000 | 00.000 |
000000 00000000000 | Formerly VC-backed | San Francisco, CA | 000 | 00.000 | 000000000 | 00.000 |
000 000000000000 | Formerly VC-backed | Epalinges, Switzerland | 000 | 00.000 | 00000000 | 00.000 |
Sunesis Board Members (16)
Name | Representing | Role | Since |
---|---|---|---|
James Young Ph.D | Self | Chairman | 000 0000 |
Sunesis Signals
Growth Rate

Growth

Size Multiple


Key Data Points
Twitter Followers
5.5k

Similarweb Unique Visitors
15.0K

Majestic Referring Domains
314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.
Request a free trialSunesis Former Investors (21)
Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
---|---|---|---|---|---|
Abingworth | Venture Capital | Minority | 000 0000 | 000000 0 | |
Aisling Capital | Venture Capital | Minority | 000 0000 | 000000 0 | |
Alta Partners | Venture Capital | Minority | 000 0000 | 000000 0 | |
Bay City Capital | Venture Capital | Minority | 000 0000 | 000000 0 | |
Biogen | Corporation | Minority | 000 0000 | 000000 0 |
Sunesis Acquisitions (1)
Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
---|---|---|---|---|---|
0000000 | 24-Feb-2021 | 0000000 00 | Drug Discovery | 0000 0000 |